TWI865760B - 阿立哌唑注射用製劑之投予方法 - Google Patents

阿立哌唑注射用製劑之投予方法 Download PDF

Info

Publication number
TWI865760B
TWI865760B TW110112186A TW110112186A TWI865760B TW I865760 B TWI865760 B TW I865760B TW 110112186 A TW110112186 A TW 110112186A TW 110112186 A TW110112186 A TW 110112186A TW I865760 B TWI865760 B TW I865760B
Authority
TW
Taiwan
Prior art keywords
aripiprazole
salt
injection preparation
injection
days
Prior art date
Application number
TW110112186A
Other languages
English (en)
Chinese (zh)
Other versions
TW202200142A (zh
Inventor
馬修 哈理
曉峰 王
燕琳 王
阿拉什 羅歐芬尼安
Original Assignee
日商大塚製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75581573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI865760(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 日商大塚製藥股份有限公司 filed Critical 日商大塚製藥股份有限公司
Publication of TW202200142A publication Critical patent/TW202200142A/zh
Application granted granted Critical
Publication of TWI865760B publication Critical patent/TWI865760B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
TW110112186A 2020-04-01 2021-04-01 阿立哌唑注射用製劑之投予方法 TWI865760B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
US63/003,544 2020-04-01

Publications (2)

Publication Number Publication Date
TW202200142A TW202200142A (zh) 2022-01-01
TWI865760B true TWI865760B (zh) 2024-12-11

Family

ID=75581573

Family Applications (4)

Application Number Title Priority Date Filing Date
TW110112186A TWI865760B (zh) 2020-04-01 2021-04-01 阿立哌唑注射用製劑之投予方法
TW110112185A TWI906279B (zh) 2020-04-01 2021-04-01 阿立哌唑治療之劑量起始方法
TW113142852A TW202523329A (zh) 2020-04-01 2021-04-01 阿立哌唑注射用製劑之投予方法
TW114148822A TW202615022A (zh) 2020-04-01 2021-04-01 阿立哌唑治療之劑量起始方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW110112185A TWI906279B (zh) 2020-04-01 2021-04-01 阿立哌唑治療之劑量起始方法
TW113142852A TW202523329A (zh) 2020-04-01 2021-04-01 阿立哌唑注射用製劑之投予方法
TW114148822A TW202615022A (zh) 2020-04-01 2021-04-01 阿立哌唑治療之劑量起始方法

Country Status (16)

Country Link
US (6) US20230129919A1 (cg-RX-API-DMAC7.html)
EP (3) EP3941470A1 (cg-RX-API-DMAC7.html)
JP (4) JP7584535B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240165486A (cg-RX-API-DMAC7.html)
CN (3) CN115397420A (cg-RX-API-DMAC7.html)
AU (2) AU2021248212A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022018721A2 (cg-RX-API-DMAC7.html)
CA (3) CA3163321C (cg-RX-API-DMAC7.html)
ES (1) ES2995466T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241574T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069157T2 (cg-RX-API-DMAC7.html)
MX (2) MX2022012354A (cg-RX-API-DMAC7.html)
PL (1) PL4125903T3 (cg-RX-API-DMAC7.html)
TW (4) TWI865760B (cg-RX-API-DMAC7.html)
WO (2) WO2021201238A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202210633B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US20230129919A1 (en) 2020-04-01 2023-04-27 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
WO2024194955A1 (en) 2023-03-17 2024-09-26 Otsuka Pharmaceutical Co., Ltd. Methods of dispersing aripiprazole injectable preparations
CN120957722A (zh) 2023-04-26 2025-11-14 大塚制药株式会社 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190099494A1 (en) * 2012-04-23 2019-04-04 Otsuka Pharmaceutical Co., Ltd. Injectable preparation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
KR101892745B1 (ko) 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
CA2655335C (en) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
KR20200010320A (ko) 2017-05-16 2020-01-30 보우 리버 엘엘씨 치료 방법
AU2019230014B2 (en) * 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
US20230129919A1 (en) 2020-04-01 2023-04-27 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190099494A1 (en) * 2012-04-23 2019-04-04 Otsuka Pharmaceutical Co., Ltd. Injectable preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
期刊 Citrome L. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Rev Neurother. 2017/09/04 *
期刊 Hard ML, Mills RJ, Sadler BM, Wehr AY, Weiden PJ, von Moltke L. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. CNS Drugs. 2017/06/08
期刊 Hard ML, Mills RJ, Sadler BM, Wehr AY, Weiden PJ, von Moltke L. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. CNS Drugs. 2017/06/08; *

Also Published As

Publication number Publication date
BR112022018721A2 (pt) 2022-11-01
MX2022012353A (es) 2022-10-31
HUE069157T2 (hu) 2025-02-28
US20230129919A1 (en) 2023-04-27
KR20220161403A (ko) 2022-12-06
TWI906279B (zh) 2025-12-01
TW202200142A (zh) 2022-01-01
ZA202210633B (en) 2025-01-29
KR20240165486A (ko) 2024-11-22
AU2021248212A1 (en) 2022-12-01
CA3136727A1 (en) 2021-10-07
EP3941470A1 (en) 2022-01-26
MX2022012354A (es) 2022-10-31
EP4125903A1 (en) 2023-02-08
JP7584535B2 (ja) 2024-11-15
ES2995466T3 (en) 2025-02-10
US12691056B2 (en) 2026-07-28
WO2021201239A1 (en) 2021-10-07
CN119792290A (zh) 2025-04-11
US20240374506A1 (en) 2024-11-14
JP7891516B2 (ja) 2026-07-16
EP4125903B1 (en) 2024-10-09
JP2023520004A (ja) 2023-05-15
KR102732030B1 (ko) 2024-11-20
EP4467194A3 (en) 2025-01-08
AU2021245713A1 (en) 2022-12-01
PL4125903T3 (pl) 2025-02-03
JP2025176037A (ja) 2025-12-03
CA3163321A1 (en) 2021-10-07
JP7733000B2 (ja) 2025-09-02
US20220160621A1 (en) 2022-05-26
US20230225962A1 (en) 2023-07-20
TW202523329A (zh) 2025-06-16
EP4125903C0 (en) 2024-10-09
KR20220161402A (ko) 2022-12-06
TW202200141A (zh) 2022-01-01
WO2021201238A1 (en) 2021-10-07
BR112022018647A2 (pt) 2022-11-08
JP2023519425A (ja) 2023-05-10
CN115397420A (zh) 2022-11-25
US20260034053A1 (en) 2026-02-05
EP4467194A2 (en) 2024-11-27
CN115379842A (zh) 2022-11-22
CA3163321C (en) 2023-12-19
CA3212191A1 (en) 2021-10-07
HRP20241574T1 (hr) 2025-01-31
US20260115131A1 (en) 2026-04-30
JP2025020306A (ja) 2025-02-12
TW202615022A (zh) 2026-04-16

Similar Documents

Publication Publication Date Title
KR102732030B1 (ko) 아리피프라졸 주사가능한 제제의 투여 방법
US11344547B2 (en) Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
JP6353577B2 (ja) 組み合わせ組成物
KR102794804B1 (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
EP3785698A1 (en) Edaravone pharmaceutical composition
CN104918619A (zh) 稳定的肠胃外dnj组合物
RU2592983C2 (ru) Комбинированная терапия, включающая вемурафениб и интерферон, для применения в лечении рака
AU2015323321A1 (en) Long acting pharmaceutical compositions
JP2023552149A (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
JP2023551009A (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
JP5872551B2 (ja) パラセタモールを含む医薬組成物およびその製造法
CN114466683A (zh) 治疗方法及其用途
KR20100124860A (ko) 독소필린을 포함하는 변형 방출 조성물
HK40077871A (en) Methods of administering an aripiprazole injectable preparation
EP4647082A1 (en) Pharmaceutical composition comprising a cgrp receptor antagonist for the treatment of acute migraine
CN107921023A (zh) 用于治疗偏头痛的包含舒马曲坦的药物组合物
WO2022122040A1 (zh) 白果内酯或银杏内酯组合物在制备镇静药物中的应用
CA3117345A1 (en) Treatment and prevention of premature ejaculation (pe)
HK1185808B (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer